‹ ›
MYP_001829
← PREVIOUS NEXT → BACK
Basic Information
P46(derived from E2 envelope protein of GB virus C)
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Standard
18 amino acids
C85H135N19O28S2
Standard
Sequence
DTVVELSEWGVPCATCIL
Physicochemical Analysis
1935.22 Da
4.05
-3.25
-3.49
-0.1807
0.88
0.33
0.37
14.89
118.89
0.0556
5500.00
5625.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
737.61
-5.55
27.0
27.0
58.0
134.0
3.0
17.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0034881 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 | gp41-induced cell; -cell; CEM-174 cells
428.8 μM
IC50
Mammalian: 1.1 h; Yeast: 3 min; E. coli: >10 h
PaperEffect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. | Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. | J Med Chem. 2010 Aug 26;53(16):6054-63. | DOI:10.1021/jm100452c | PMID:20718496 PMID20718496 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20718496/
RECORD: Rec_0058194 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV Fusion inhibition
inhibition of HIV
24.1 μM
IC50
Mammalian: 1.1 h; Yeast: 3 min; E. coli: >10 h
PaperEffect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. | Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. | J Med Chem. 2010 Aug 26;53(16):6054-63. | DOI:10.1021/jm100452c | PMID:20718496 PMID20718496 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20718496/
RECORD: Rec_0083673 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
inhibition of HIV(HXB2) infection in TZM-bl Cells
39.9 μM
IC50
PMID20718496 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20718496/
RECORD: Rec_0116596 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1
39.9 μM
IC50
Mammalian: 1.1 h; Yeast: 3 min; E. coli: >10 h
PaperEffect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. | Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. | J Med Chem. 2010 Aug 26;53(16):6054-63. | DOI:10.1021/jm100452c | PMID:20718496 PMID20718496 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20718496/
RECORD: Rec_0217864 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Defensin
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
HIV-1
PMID20718496 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20718496/
1 2 3 NEXT LAST
Showing 5 records on this page · Page 1 of 3